High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial

Nishikido, Toshiyuki; Oyama, Jun‐ichi; Keida, Takehiko; Ohira, Hiroshi; Node, Koichi

doi:10.1016/j.jjcc.2015.05.017

Cited by 30 publications

(21 citation statements)

References 28 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 , the lipid-lowering therapies such as atorvastatin 20 mg/d plus ezetimibe 10 mg/d and atorvastatin 40 mg/d were compared in the aspect of lipid-lowering efficacy. The lipid-lowering efficacy of both strategies was in accordance with the results reported in previous studies [ 9 – 11 ]. Abundant evidences demonstrated that the lower the level of LDL-C reached, the better the reduction of cardiovascular events [ 12 – 14 ].…”

Section: Discussionsupporting

confidence: 91%

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers

Guo

Zhu

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundAchievement of low-density lipoprotein cholesterol (LDL-C) goal is the most important for the patients with atherosclerotic cardiovascular diseases (ASCVD) who received lipid-lowering therapy. It is unclear that whether combination of ezetimibe with statin is superior to double-dose of statin regarding both of the lipid-lowering efficacy and improvement of inflammation in Chinese patients with ASCVD. Therefore, this study was performed to compare the effects of these two regimes on lipid profiles and inflammation markers.MethodsIn this randomized control study, ninety eight patients with ASCVD, who were naïve to statins or other lipid-lowering agents, were enrolled into the study, and randomly assigned into two groups, A40 group (atorvastatin 40 mg/d, n = 50), A20E10 group (atorvastatin 20 mg/d combined with ezetimibe 10 mg/d, n = 48).The patients were followed up at week 4 and week 12 after treatment. The lipid profiles and oxidative low-density lipoprotein cholesterol (ox-LDL) were measured at the end of study.ResultsThere were no differences in clinical characteristics including lipid, ox-LDL and hypersensitive C reactive protein (Hs-CRP) among groups at baseline. However, the average level of LDL-C was lower in group A20E10 than that in group A40 significantly (1.59 ± 0.44 mmol/L vs 1.99 ± 0.56 mmol/L, p = 0.001) during follow-up at week 12 after treatment. Importantly, the higher rate of achievement of LDL-C goal was attained at group of combination statin with ezetimibe (79.2% in group A20E10 vs 50.0% in group A40, p = 0.016). The difference of the level of ox-LDL between both the groups after 12 weeks treatment had not statistical significance (3.63 ± 1.13 U/L in group A20E10 vs 4.14 ± 1.32 U/L in group A40, p = 0.077).Similarly, the level of Hs-CRP between both the groups after treatment was not significantly different (p > 0.05).ConclusionsIn this randomized study, the data showed that a combination of moderate statin and ezetimibe achieved more reduction of LDL-C compared to the double-dose statin but similar impact on inflammation markers.

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers

Guo

Zhu

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…CVD is multifactorial, and various risk factors that work through numerous mechanisms in the cardiovascular system affect the severity of disease risk. Statins mainly affect circulating concentrations of LDL-cholesterol, but other parameters of the lipid profile or markers of inflammation independently affect CVD progression and outcomes, such as HDL-cholesterol, LDL-cholesterol particle distribution, and elevated C-reactive protein and triglyceride concentrations [ 28 , 29 ]. The remaining risk of CVD outcomes in statin-treated patients is related to the independent effects of these risk factors and residual atherosclerosis.…”

Section: Statins: Mode Of Actionmentioning

confidence: 99%

The Role of n-3 Long Chain Polyunsaturated Fatty Acids in Cardiovascular Disease Prevention, and Interactions with Statins

2018

View full text Add to dashboard Cite

Decreases in global cardiovascular disease (CVD) mortality and morbidity in recent decades can be partly attributed to cholesterol reduction through statin use. n-3 long chain polyunsaturated fatty acids are recommended by some authorities for primary and secondary CVD prevention, and for triglyceride reduction. The residual risk of CVD that remains after statin therapy may potentially be reduced by n-3 long chain polyunsaturated fatty acids. However, the effects of concomitant use of statins and n-3 long chain polyunsaturated fatty acids are not well understood. Pleiotropic effects of statins and n-3 long chain polyunsaturated fatty acids overlap. For example, cytochrome P450 enzymes that metabolize statins may affect n-3 long chain polyunsaturated fatty acid metabolism and vice versa. Clinical and mechanistic study results show both synergistic and antagonistic effects of statins and n-3 long chain polyunsaturated fatty acids when used in combination.

show abstract

“…However, a number of clinical trials showed 60%–70% of CVD events continue to occur despite LDL-lowering therapy, which may be due to residual risks associated with lipid abnormalities especially atherogenic dyslipidaemia, including increased TG levels and reduced HDL-C levels. 20 21 Therefore, a need for new targets to compliment the measures of LDL-C lowering has been suggested. Recent studies identified LDL-C:HDL-C ratio as a better biomarker to predict both AS progression and CVD than LDL-C or HDL-C alone.…”

Section: Introductionmentioning

confidence: 99%

LDL-C:HDL-C ratio and common carotid plaque in Xinjiang Uygur obese adults: a cross-sectional study

Zhao

Liu

Wang³

et al. 2018

BMJ Open

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to explore the relationship between low-density lipoprotein cholesterol:high-density lipoprotein cholesterol (LDL-C:HDL-C) ratio and common carotid atherosclerotic plaque (CCAP) among obese adults of Uygur community in Xinjiang, China.DesignA hospital-based cross-sectional study.SettingFirst Affiliated Hospital of Xinjiang Medical University.ParticipantsA total of 1449 obese adults of Uygur population who were free of coronary artery disease were included in our study from 1 January 2014 to 31 December 2016.MethodologyLipid profiles, other routine laboratory parameters and intima-media thickness of the common carotid artery were measured in all participants. Multivariate logistic regression analysis was used to examine the association between LDL-C:HDL-C ratio and CCAP.ResultsFour hundred and fifteen (28.64%) participants had CCAP. Participants with CCAP had significantly higher LDL-C:HDL-C ratio compared with those without CCAP (3.21 [2.50, 3.88] vs 2.33 [1.95, 2.97], p<0.001). Multivariate logistic regression analysis showed high LDL-C:HDL-C ratio as independent predictor of CCAP after adjusting for conventional cardiovascular risk factors. The top LDL-C:HDL-C ratio quartile (≥3.25) had an OR of 9.355 (95% CI 6.181 to 14.157) compared with the bottom quartile (<2.07) of LDL-C:HDL-C ratio (p<0.001) after adjustment for age, body mass index, smoking, diabetes mellitus and serum level of total cholesterol.ConclusionCCAP is highly prevalent in Uygur obese adults. A high LDL-C:HDL-C ratio is an independent predictor of CCAP. It may help identify obese individuals who are at high risk of CCAP and who may benefit from intensive LDL-lowering therapy.

show abstract

High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial

Abstract: High-dose statin therapy significantly reduced the sd-LDL and MDA-LDL components of atherosclerotic lipoproteins without adverse events in comparison with low-dose statin therapy.

Cited by 30 publications

References 28 publications

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers

The Role of n-3 Long Chain Polyunsaturated Fatty Acids in Cardiovascular Disease Prevention, and Interactions with Statins

LDL-C:HDL-C ratio and common carotid plaque in Xinjiang Uygur obese adults: a cross-sectional study

Contact Info

Product

Resources

About